|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
4,280.00 JPY |
-0.83% | -2.10% | +2.37% | |
Published on 05/08/2025 at 05:51
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Takeda Pharmaceutical Fiscal Q4 Core Earnings Fall, Revenue Rises |
04:53am |
MT |
|
Takeda’s Annual Net Profit Slumps on Expenses, Costs |
04:09am |
DJ |
|
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 |
03:50am |
CI |
|
Jefferies Adjusts Takeda Pharmaceutical Company’s Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy |
May. 06 |
MT |
|
Trump’s tariffs and threatened trade actions |
May. 05 |
RE |
|
Trump’s tariffs and threatened trade actions |
May. 05 |
RE |
|
Novavax To Receive $19.5 Million Upfront Payment Under Amended Agreement With Takeda |
May. 05 |
RE |
|
Novavax, Inc. Enter into A Collaboration and Exclusive License Agreement, as Amended, with Takeda Pharmaceutical Company Limited |
May. 05 |
CI |
|
Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan |
May. 05 |
MT |
|
Novavax Announces Improved Terms For Collaboration, License Agreement With Takeda For Nuvaxovid In Japan |
May. 05 |
RE |
|
Takeda Awards $13.8 Mln To U.S. Nonprofit Partners |
Apr. 30 |
RE |
|
Australia’s CSL evaluates China tariff exemptions for its US-made drugs |
Apr. 30 |
RE |
|
Takeda Completes Share Buyback; Acquires 11.8 Million Shares |
Apr. 22 |
MT |
|
Tranche Update on Takeda Pharmaceutical Company Limited’s Equity Buyback Plan announced on January 30, 2025. |
Apr. 22 |
CI |
|
Takeda Pharmaceutical Company Limited ‘s Equity Buyback announced on January 30, 2025 has closed with 23,367,100 shares, representing 1.47% for ¥99,955.87 million. |
Apr. 20 |
CI |
|
Blackrock Raises Stake In Takeda Pharmaceutical To 8.43% From 7.33%, Filing Shows |
Apr. 17 |
RE |
|
Trump’s tariffs and threatened trade actions |
Apr. 14 |
RE |
|
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs — Update |
Apr. 09 |
DJ |
|
Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines |
Apr. 09 |
DJ |
|
Trump’s tariffs and threatened trade actions |
Apr. 07 |
RE |
|
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading |
Apr. 03 |
MT |
|
Pharma stocks survive market rout on tariff exemption, but uncertainty continues |
Apr. 03 |
RE |
|
Tranche Update on Takeda Pharmaceutical Company Limited’s Equity Buyback Plan announced on January 30, 2025. |
Apr. 01 |
CI |
|
Trump’s tariffs and threatened trade actions |
Mar. 31 |
RE |
|
Takeda’s Hyqvia Receives Expanded Market Authorization As Maintenance Therapy For CIDP |
Mar. 27 |
RE |
4502: Dynamic Chart
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company’s research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
More about the company
Buy
Last Close Price
4,316.00JPY
Average target price
5,041.94JPY
Spread / Average Target
+16.82%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
